National Health (Immunisation Program Designated Vaccines) Variation Determination 2012 (No. 1) (Cth)
National Health (Immunisation Program – Designated Vaccines) Variation Determination 2012 (No. 1)[1]
National Health Act 1953
I, JULIANNE QUAINE, Delegate of the Minister for Health, make this Determination under subsections 9B (2) and (5) of the National Health Act 1953.
Dated 4 October 2012
JULIANNE QUAINE
Assistant Secretary
Health Protection Programs Branch
Department of Health and Ageing
Delegate of the Minister for Health
Name of Determination
This Determination is the National Health (Immunisation Program – Designated Vaccines) Variation Determination 2012 (No. 1).
Commencement
This Determination will commence on the day after it is registered on Federal Register of Legislative Instruments.
Variation of National Health (Immunisation Program – Designated Vaccines) Determination 2012 (No 1)
Schedule 1 varies the National Health (Immunisation Program – Designated Vaccines) Determination 2012 (No 1)
Schedule 1 Variations
[1] Subsection 7(1)
omit
109
substitute
110
[2] Subsection 7(2)
omit
111
substitute
112
[3] Subsection 7(3)
omit
112
substitute
113
[4] Schedule 1
omit
Part 1
substitute
Part 1 Bacterial vaccines
| Item | Vaccine and the circumstances in which vaccine may be provided | Brand | Formulation | Active ingredient and strength | Number and timing of doses |
| 101 | Vaccine Diphtheria, tetanus and pertussis (adult/adolescent) Circumstances Vaccine may be provided to a child who is at least 10 years but less than 18 years old. | Boostrix | Injection (0.5mL) | Each of the following: (a) diphtheria toxoid — not less than 2 IU; (b) tetanus toxoid — not less than 20 IU; (c) PT — 8 µg; (d) FHA — 8 µg; (e) PRN — 2.5 µg | 1 dose (booster) |
| 102 | Vaccine Diphtheria, tetanus and pertussis (adult/adolescent) Circumstances Vaccine may be provided to a child who is at least 10 years but less than 18 years old. | Adacel | Injection (0.5mL) | Each of the following: (a) diphtheria toxoid — not less than 2 IU; (b) tetanus toxoid — not less than 20 IU; (c) PT — 2.5 µg; (d) FHA — 5 µg; (e) PRN — 3 µg (f) FIM 2+3 — 5 µg | 1 dose (booster) |
| 103 | Vaccine Haemophilus influenzae type b (Hib) (monovalent PRP‑T) Circumstances Vaccine may be provided to a child who is about 12 months old. | ActHib or Hiberix | Refrigerated lyophilised preparation for injection (0.5mL) with separate diluent | Purified Hib capsular polysaccharide conjugated to tetanus toxoid — 10 µg | 1 dose (booster) |
| 104 | Vaccine Haemophilus influenzae type b (Hib) (monovalent PRP‑OMP) Circumstances Vaccine may be provided to a child who is about 2, 4 or 12 months old. | Pedvax | Vial for injection (0.5mL) | Purified Hib capsular polysaccharide conjugated to meningococcal protein — 7.5 µg | 3 doses |
| 105 | Vaccine Haemophilus influenzae type b (Hib) and Meningococcal C Circumstances Vaccine may be provided to a child who is about 12 months old. | Menitorix | Refrigerated lyophilised preparation for injection (0.5mL) with separate diluent | Each of the following : (a) Hib capsular polysaccharide conjugated to tetanus toxoid- 5 µg (b) Group C meningococcal polysaccharide conjugated to tetanus toxoid- 5 µg | 1 dose |
| 106 | Vaccine Meningococcal C (conjugate) Circumstances Vaccine may be provided: (a) to a child who is about 12 months old; or (b) in the period commencing on 1 January 2006 and ending at the end of 30 June 2007, to a person: (i) who, on 1 January 2003, was at least 1 year but less than 20 years of age; and (ii) who has not received a vaccine mentioned in this item or item 106 or 107 | Meningitec | Injection (0.5mL) | Meningococcal group C oligosaccharide conjugated to diphtheria protein — 10 µg | 1 dose |
| 107 | Vaccine Meningococcal C (conjugate) Circumstances Vaccine may be provided: (a) to a child who is about 12 months old; or (b) in the period commencing on 1 January 2006 and ending at the end of 30 June 2007, to a person: (i) who, on 1 January 2003, was at least 1 year but less than 20 years of age; and (ii) who has not received a vaccine mentioned in this item or item 105 or 107 | Menjugate | Refrigerated lyophilised preparation for injection (0.5mL) with separate diluent | Meningococcal group C oligosaccharide conjugated to diphtheria protein — 10 µg | 1 dose |
| 108 | Vaccine Meningococcal C (conjugate) Circumstances Vaccine may be provided: (a) to a child who is about 12 months old; or (b) in the period commencing on 1 January 2006 and ending at the end of 30 June 2007, to a person: (i) who, on 1 January 2003, was at least 1 year but less than 20 years of age; and (ii) who has not received a vaccine mentioned in this item or item 105 or 106 | NeisVac‑C | Injection (0.5mL) | Meningococcal group C oligosaccharide conjugated to tetanus toxoid protein — 10 µg | 1 dose |
| 109 | Vaccine Pneumococcal (conjugate, 7‑valent) Circumstances Vaccine may be provided to: (a) a child who is about 2, 4 or 6 months old; or (b) a child who is about 12 months of age and is a member of a medical risk group | Prevenar | Injection (0.5mL) | Polysaccharides of Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F and 23F conjugated to diphtheria protein — 2 µg of each of serotypes 4, 9V, 14, 18C, 19F and 23F, and 4 µg of serotype 6B | 3 or 4 doses |
| 110 | Vaccine Pneumococcal (conjugate, 13‑valent) Circumstances Vaccine may be provided: (a) to a child who is about 2, 4 or 6 months old; and (b) to a child who is about 12 months of age and is a member of a medical risk group; or (c) Vaccine may be provided in the circumstances set out in subsection 7 (1) | Prevenar 13 | Injection (0.5mL) | Polysaccharides of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F - 2.2 µg of each of serotype, and 4.4 μg of serotype 6B | 3 or 4 doses for a primary course or a single supplementary dose. |
| 111 | Vaccine Pneumococcal (conjugate, 10‑valent) Circumstances Vaccine may be provided to a child who is about 2, 4 or 6 months old, or 18 months old. | Synflorix | Injection (0.5mL) | Polysaccharides of Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14 and 23F conjugated to protein D (a surface protein from non-typeable Haemophilus influenzae), serotype 18C conjugated to tetanus toxoid protein and serotype 19F conjugated to diptheria toxoid protein – 1 µg of each 1, 4, 6B, 7F, 9V, 14 and 23F and 3 µg of 4, 18C and 19F. | 4 dose |
| 112 | Vaccine Pneumococcal (polysaccharide, 23‑valent) Circumstances Vaccine may be provided in the circumstances set out in subsection 7 (2) | PneumoVax 23 | Injection (0.5mL) | Polysaccharides of Streptococcus pneumoniae serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F — 25 µg of each serotype | 1 to 3 doses |
| 113 | Vaccine Q fever Circumstances Vaccine may be provided in the circumstances set out in subsection 7 (3) | Q‑Vax | Injection (0.5mL) | Killed Coxiella burnetii — 25 µg | 1 dose |
[6] Schedule 1, Part 2, Item 212
omit
female
substitute
person
[7] Schedule 1, Part 2, Item 212
omit
(b)a female who, between 1 March 2007 – 30 June 2009, is at least 13 years old but less than 27 years old and has received at least one before 1 July 2009.
substitute
(b) A male who, between 1 February 2013 and 31 December 2015, is at least 13 years old but less than 16 years old.
[1]Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See
0
0
0